04:36 AM EDT, 03/16/2026 (MT Newswires) -- Astrazeneca ( AZN ) said Monday its Imfinzi human monoclonal antibody has received European Union approval to treat adults with resectable, early-stage, and locally advanced gastric and gastroesophageal junction cancers.

The regimen includes two cycles of Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel, or FLOT, chemotherapy, according to the company.

Astrazeneca ( AZN ) said the EU's decision was based on the company's Matterhorn phase 3 study, in which the Imfinzi and FLOT perioperative regimen showed a "statistically significant and clinically meaningful survival improvement", lowering the death risk by 22% in comparison to chemotherapy alone.

Imfinzi and FLOT chemotherapy is approved in the US and other countries based on the Matterhorn results, the company said.